SMC approves funding for four new medicines on the NHS
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
Read More
Tag: Zeposia
NICE no for BMS’ multiple sclerosis drug Zeposia
Cost-effectiveness estimates ‘uncertain’, according to NICE
Read More
BMS’ Zeposia hits the mark in ulcerative colitis
Oral S1P receptor modulator hit both primary endpoints in a phase III trial
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
